Teva Pharmaceuticals

TEVA

Market cap $22.7B

Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.

Billionaire Stanley Druckenmiller has earned a spot among the best investors ever. Through more than four decades of investing, Druckenmiller has yet to post a year where his investments finished in the red, and that includes during the Great Recession in 2008-09, when his fund at the time posted an 11% gain.

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (Euronext: MEDCL), announced today that the U.S. Food and Drug Administration (FDA) has approved UZEDY® (risperidone) as a once-monthly extended-release injectable suspension as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder (BD-I) in adults. The approval is based on existing clinical data for UZEDY, coupled with Model-Informed Drug Development (MIDD) methodologies that leverage previous findings on the safety and efficacy of risperidone formulations already approved for BD-I.

Teva Pharmaceutical Industries Limited is regaining investor interest as restructuring efforts drive margin improvements and unlock pipeline potential. Turnaround: company is changing to a more profitable company. Duvakitug and the company's other pipelines have significant future potential.

For a lot of investors, earnings season is the highlight of every quarter. It's the roughly six-week period where most S&P 500 components report their operating results and give investors an inside look at how "healthy" corporate America really is.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Drugmakers know the script by now. Washington picks a handful of blockbuster medicines, haggles with their makers, and then publishes the “maximum fair price” that Medicare will pay.

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website.

Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment market. So, global sales of Austedo, widely used among neurologists for the treatment of tardive dyskinesia, reached $498 million in Q2 2025, an increase of 21.2% quarter-on-quarter. On September 20, Teva announced additional clinical data showing that taking Austedo XR led to significant improvements in social and emotional well-being.